Last updated on February 2018

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.


Brief description of study

To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.

Clinical Study Identifier: NCT02947165

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Taipei, Taiwan
  Connect »

Todd M. Bauer

Novartis Investigative Site
Nashville, TN United States
  Connect »

Ignacio Garrido Laguna

Novartis Investigative Site
Salt Lake City, UT United States
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Hong Kong, Hong Kong
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Kashiwa, Japan
  Connect »